2020
SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn’s Disease
Dimopoulos C, Al-Bawardy B. SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn’s Disease. Inflammatory Bowel Diseases 2020, 26: e153-e154. PMID: 33043966, PMCID: PMC7665493, DOI: 10.1093/ibd/izaa275.Peer-Reviewed Case Reports and Technical Notes
2014
Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C
Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM. Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. Mayo Clinic Proceedings 2014, 89: 595-601. PMID: 24661475, PMCID: PMC4160303, DOI: 10.1016/j.mayocp.2014.01.024.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansInterferonsMaleMiddle AgedOligopeptidesProspective StudiesRibavirinTreatment OutcomeConceptsRapid virologic responseChronic hepatitis CVirologic responseEarly virologic responseTriple therapyDual therapyHepatitis CP-IFNSustained virologic responseTreatment response categoriesTreatment-naive patientsPhase 3 trialRBV dose reductionPrior nonresponsePrior relapseCirrhosis statusProspective databaseViral hepatitisHemoglobin levelsAntiviral therapyWeek 4Dose reductionMean decreaseEligibility criteriaPatients